A Mortality Gene(s) for the Human Adenocarcinoma Line HeLa Maps to a 130-kb Region of Human Chromosome 4q22-q23  by Bryce, Steven D. et al.
A Mortality Gene(s) for the Human Adenocarcinoma Line HeLa
Maps to a 130-kb Region of Human Chromosome 4q22-q23
Steven D. Bryce*, Vivienne Morrison*, Nicola J. Craig*, Nicholas R. Forsyth*, Sara A. Fitzsimmons*,
Hazel Ireland*, Andrew P. Cuthbert y, Robert F. Newbold y and E. Kenneth Parkinson*
*Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Garscube Estate,
Switchback Road, Bearsden, Glasgow G61 1BD, Scotland, UK; yDepartment of Biological Sciences,
Brunel University, Uxbridge, Middlesex UB8 3PH, UK
Abstract
Human chromosome 4 was previously shown to elicit
features of senescence when introduced into cell lines
that map to complementation group B for senescence,
including HeLa cells. Subsequently, a DNA segment
encoding the pseudogene Mortality Factor 4 (MORF4 )
was shown to reproduce some of the effects of the intact
chromosome 4 and was suggested to be a candidate
mortality gene. We have identified multiple MORF4
alleles in several cell lines and tissues by sequencing
and have failed to detect any cancer-specific mutations
in three of the complementation group B lines (HeLa,
T98G, and J82). Furthermore,MORF4was heterozygous
in these lines. These results question whether MORF4
is the chromosome 4 mortality gene. To map other can-
didate mortality gene(s) on this chromosome, we em-
ployed microcell -mediated monochromosome transfer
to introduce either a complete copy, or defined frag-
ments of the chromosome into HeLa cells. The intro-
duced chromosome 4 fragments mapped the mortality
gene to a region between the centromere and the
marker D4S2975 (4q27), thus excluding MORF4, which
maps to 4q33-q34.1. Analysis of microsatellite markers
on the introduced chromosome in 59 immortal segre-
gants identified a frequently deleted region, spanning
the markers BIR0110 and D4S1557. This defines a new
candidate interval of 130 kb at 4q22-q23.
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Introduction
Microcell -mediated monochromosome transfer (MMCT)
experiments suggest that several cancer mortality genes
may exist [6,11,13,15,19,21,22,26–28,31,33–35,38,41,44],
but in most cases, the genes responsible have not been
identified, and with the exception of those that downregulate
telomerase [13,28,38], their function is unknown. Chromo-
some 4 has been shown to carry a mortality gene(s) for cell
lines mapping to mortality complementation group B [26] and
a candidate for one of these genes, Mortality Factor 4
(MORF4 ), was described recently [6 ].
We investigated the candidacy of the MORF4 mortality
gene and found no evidence for cancer -specific alterations in
its coding sequence [9] and have extended this observation
to include the complementation group B cell lines (HeLa,
T98G, and J82). We, therefore, searched for other candidate
regions of chromosome 4 by a combination of MMCT and
deletion analysis. Our investigations revealed a candidate




HeLa, T98G, and 143B cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) plus 10% fetal bovine
serum (FBS). Mouse A92 cells containing a single copy of
human chromosome 4 or chromosome 4 fragments carrying
the selectable markers for hygromycin B and G418 resist-
ance (HyTK4/4i24/4i30/4i33 [14,17] was grown in DMEM
plus 10% FBS and 800 U/ml hygromycin B; Calbiochem
Novachem, UK).
DNA Extraction
DNA was extracted from typically 106 to 107 cultured cells
using the QIAamp tissue kit (QIAgen, Crawley, West Sussex,
UK) according to the manufacturer’s ‘‘blood and body fluid’’
protocol.
MORF4 Sequencing
A 1.5-kb genomic fragment containing the MORF4 se-
quence was amplified, purified, and sequenced as previously
described [9].
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MMCT
Microcells were prepared as described previously [14]
and the purified microcell pellet was then resuspended in
50 g/ml phytohemagglutinin in serum-free medium and
applied to 70% to 80% confluent recipient cells. Plates were
left for 2 hours to allow attachment of microcells before fusion
to the recipient cells in the presence of 42.5% polyethylene
glycol (PEG 1000; Sigma, Poole, Dorset, UK) and 8.5%
DMSO in serum-free medium. Following a 24-hour recovery
period in complete medium, fused cells were replated in
standard medium and the following day placed under
selection in medium containing 300 (HeLa) and 500
(143B) U/ml hygromycin B. Doses represented the mini-
mum required for complete killing of mock- fused cultures of
each line and hence the minimum dose required. The careful
selection of drug dose avoids artifacts due to incomplete
hygromycin resistance. Those colonies, which overcame
selection in hygromycin B, were picked and cultured for a
further 5 to 6 weeks before harvesting and extracting DNA.
An immortal segregant chromosome 4 hybrid culture was
classified as one that proliferated through at least 25
population doublings and the control hybrids were cultured
for the same number of doublings prior to molecular genetic
analysis. The immortal segregants were all maintained in the
appropriate dose of hygromycin.
Chromosome Painting
Metaphase chromosome spreads were prepared essen-
tially as described by Ref. [14]. Metaphase spreads were
hybridized with a chromosome 4 probe prepared from flow-
sorted chromosome 4 DNA and chromosome painting
carried out as described previously [12].
Marker Alleles Analysis
Total reaction volumes were 10 l containing 40 ng of
genomic DNA, 10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM
MgCl2, 10% dimethylsulphoxide, 1 M of each oligonucleo-
tide primer, 200 M concentrations of each deoxynucleotide
triphosphate, 0.4 l of [a32P]dCTP (24.7 kBq/l ), and 0.5 U
of Taq polymerase (Advanced Biotechnologies, Epsom,
Surrey, UK). Reactions were subjected to an initial dena-
turation phase of 5 minutes at 948C, followed by 30 cycles of
30 seconds at 948C, 30 seconds at 55 to 658C, and 30
seconds at 728C, and a final extension phase of 7 minutes at
728C. Radiolabeled samples were electrophoresed on 4% to
10% polyacrylamide gels under denaturing conditions.
Following a drying step, gels were then exposed to X-ray
film to visualize the resolved reaction products.
Statistics
The Fisher’s exact test was used for the comparison of
allele deletion frequencies in different groups of cells. In the
case of the immortal segregant colonies resulting from the
MMCT of chromosome 4, the allele deletion frequencies of
the transferred, wild - type chromosome 4 were compared
with the deletion frequencies of the same allele in a panel of
control chromosome 4 hybrids. The control panel of hybrids
comprised one HeLa–chromosome 4 hybrid that displayed a
mortal phenotype and eleven 143B–chromosome 4 hybrids
that all retained an immortal phenotype. All of these control
fusions therefore constitute a measurement of the sponta-
neous loss of each allele of the transferred chromosome that
may not be consistent throughout the length of the
chromosome.
Results
MORF4 is Normal and Heterozygous in Complementation
Group B Cell Lines
We have sequenced MORF4 in three complementation
group B lines — HeLa, J82, and T98G. We found no
mutations or deletions. Any sequence differences from the
reported MORF4 sequence [6] were at polymorphic loci
previously identified in a study of squamous cell carcinoma
lines [9] and are not tumor line–specific as they were also all
found in normal fibroblasts. Table 1 lists the base present at
each of the polymorphic loci of the MORF4 sequence in the
different lines. At base positions 108 and 115 in HeLa, and at
position 49 in J82 and T98G, two different alleles are present
in the sequence. Therefore, each of the complementation
group B lines we have examined is heterozygous at the
MORF4 locus.
Introduction of Chromosome 4/Chromosome 4cen-q27
Containing Fragments Elicits a Mortal Phenotype in HeLa
Cells
We introduced, using MMCT, an intact copy of chro-
mosome 4 into either HeLa cells or, as a control, the com-
plementation group C line 143B. Following selection, 44%
(78/178) of the HeLa–chromosome 4 hybrid clones ex-
hibited a mortal phenotype following a variable delay of
approximately 4 to 25 mean population doublings (MPD).
The remaining 56% of the hybrid clones continued to grow
vigorously beyond at least 25 MPD and were considered to
have retained an immortal phenotype. We performed
chromosome painting experiments to confirm that hybrid
clones displaying the immortal phenotype had retained an
extra introduced copy of chromosome 4 (Figure 1). Analysis
Table 1. Polymorphic Loci in the MORF4 Gene.
Allele at Polymorphic Loci
49 108 115 428 615 730 865
Tumor Lines
HeLa G T A/G A /G T T G
J82 A /G T A G C A A
T98G A /G T A G C A A
Fibroblasts
31F A /G C /T A G C/T A /T A /G
63F G T A/G A /G T T G
Nucleotide( s ) at the seven polymorphic loci in the MORF4 gene (base
positions as previously described in Ref. [ 9 ] ) in three complementation group
B lines. Each of the lines is heterozygous in at least one position. Allelotypes
from normal fibroblast controls containing the same polymorphisms are
shown for comparison.
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of metaphase spreads from six different hybrid clones
revealed an average of four copies of chromosome 4 per
cell compared to an average of three for the control HeLa
metaphases. Cells displaying the mortal phenotype took on a
flattened morphology with an enlarged cytoplasm, reminis-
cent of senescent epithelial cells (Figure 2). These cells
were often multinucleate and stained positive for the
senescence-associated b -galactosidase activity (data not
shown). All (11/11) of the 143B–chromosome 4 hybrids
retained vigorous growth beyond 25 MPD and were judged
immortal by this criterion. To identify regions of chromosome
4 responsible for the restoration of mortality effect, we
introduced defined fragments of chromosome 4 (described
previously in Ref. [17] ) into HeLa cells. All three fragments
tested induced a mortal phenotype at around the same
frequency as the whole chromosome (Table 2). The
introduced chromosome 4 fragments share the region
between the markers D4S2978 and D4S2975 in common
(approximately 4cen-q27), therefore mapping the activity to
this interval.
Deletions on the Introduced Chromosome Identify a
Candidate Interval Between the Markers BIR0110 and
D4S1557
We examined hybrid clones that retain an immortal
phenotype for the loss of material from the introduced
chromosome 4, as a common region of loss might suggest
selection against a suppressor of the immortal phenotype at
that locus. Initially, we screened 59 HeLa–chromosome 4
immortal hybrids, the eleven 143B–chromosome 4 immortal
control hybrids, and as an additional control a HeLa–
chromosome 4 clone (4.70), which displayed a mortal
phenotype. Using 23 markers spaced at approximately 10
cM intervals over the length of chromosome 4, we found
allele loss from the introduced chromosome at one or more
loci with 30 (51%) of the immortal HeLa clones, with loss of
alleles at all loci examined in 12 of these clones. Figure 3A
Figure 1. Chromosome 4–specific painting in HeLa and HeLa–chromosome
4 hybrid cells. Metaphase spreads from (A ) HeLa–chromosome 4 clone and
(B ) untransferred HeLa cells hybridized with a chromosome 4–specific paint,
demonstrating the gain of an extra copy of chromosome 4 in hybrid cells.
Arrows indicate painted chromosomes.
Figure 2. Mortal clones develop a phenotype reminiscent of senescence.
Phase contrast images of cells exhibiting (A ) the characteristic flattened
morphology and enlarged cytoplasm of mortal hybrid clones and (B ) cells
from an immortal hybrid clone. Scale bar indicates 100 m.
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shows the losses from HeLa clones with discrete deletions
from the D4S2978–D4S2975 marker interval compared to
the control hybrids. Using the Fisher’s exact test, we
calculated the probability that the losses at the microsatellite
loci have occurred by chance, as assessed by comparing the
frequency of loss at each locus in the immortal HeLa hybrids
and the control clones. The significant losses with the
markers D4S423 (P<.04), D4S1570 (P<.03), and D4S406
(P<.04) and the frequent breakage of the introduced
chromosome between the markers D4S2964 and D4S423
directed us to examine the interval from D4S2964 to
D4S1570 in more detail. We used all available polymorphic
markers from the public domain databases and a number of
novel markers that we developed [17] to generate a detailed
map of the losses in this interval. The results for key markers
are shown in Figure 3B. There is no region that is lost in all
the clones tested; however, three clones lose the marker
BIR0104 while retaining the nearest surrounding markers
Figure 3. Deletion analysis in immortal HeLa–chromosome 4 hybrid clones and 143B–chromosome 4 hybrid controls. Maps of allele loss from the exogenous
chromosome 4 in selected HeLa–chromosome 4 hybrid clones and all 143B–chromosome 4 hybrid clones. Open circles (6 ) indicate retained alleles; dark filled
circles ( ) indicate allele loss; and light filled circles ( ) indicate marker not informative. Boxes indicate contiguous regions of allele loss. Map (A ) shows markers
from the 4cen -q27 region common to the chromosome 4 fragments (with 143B–chromosome 4 hybrids, the marker D4S1583 was used instead of D4S2978 ).
Marker positions were derived from the Ge´ne´thon genetic map (available at http: //www.gdb.org ). A shaded box indicates the common region of loss between
the markers D4S2964 and D4S1570. A more detailed map of this region is shown in (B ). Marker order on this finer scale is derived from the University of
California at Santa Cruz draft human genome assembly (August 2001 data freeze; http: // genome.ucsc.edu ).
Table 2. Effect of Introduction of Chromosome 4 / 4 Fragments into HeLa.
MMCT Hybrid Clones
Mortal Immortal
HeLa–4 78 44% 100 56%
HeLa–4i24 15 44% 19 56%
HeLa–4i32 5 29% 12 71%
HeLa–4i33 1 33% 2 66%
Proportions of clones exhibiting mortal or immortal phenotypes following the
introduction of chromosome 4 or three different chromosome 4 fragments into
HeLa cells.
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BIR0110 and D4S1557. This region is overlapped by larger
deletions in 23 other clones, and as such comprises the most
frequently deleted locus in the 4cen-q27 interval. We did not
find discrete deletions involving a single marker at any other
locus, and therefore consider the interval from BIR0110 to
D4S1557 to be the minimal candidate interval for the
immortality -suppressing activity. Although deletion analysis
can be confounded by the presence of fragile sites and sites
of high recombination, the analysis of our control 143B
hybrids enabled us to eliminate regions that might be lost
spontaneously. For example, D4S2975 has high rates of
allele loss in the HeLa–chromosome 4 immortal segregants,
but similar high rates of loss in the control hybrids reduce the
impact of its candidacy (P=.20). We found no allele losses
at any marker loci, including BIR0104, with the mortal HeLa–
chromosome 4 hybrid clone 4.70.
Discussion
Heterozygosity of MORF4 in Immortality Complementation
Group B Lines and an Absence of Cancer-Specific Alleles
MORF4 has been suggested as a candidate for the
complementation group B mortality gene [6]. We have
examined the sequence of MORF4 in a number of cell lines
and tissues, including the three complementation group B
lines (HeLa, J82, and T98G). We found no evidence of
cancer-specific alterations of MORF4 in these lines and the
MORF4 gene was heterozygous in all three lines. Previous
work had already shown that MORF4 showed no differences
in expression between cell lines from the different comple-
mentation groups [6]. These results, coupled with the
mapping of the chromosome 4 activity using fragment
MMCT to a region of the chromosome that does not include
MORF4, strongly suggested that MORF4 is not the com-
plementation group B gene. Therefore, we continued to
search for other candidate loci on chromosome 4 that might
harbor a mortality gene.
A Novel Chromosome 4 Locus is Associated with HeLa Cell
Immortality
First, we introduced chromosome 4 into HeLa cells and
the complementation group C line 143B as a control and
showed specific induction of the mortal phenotype in HeLa
cells, as reported previously and only when chromosome 4
was transferred [26]. The frequency of MMCT hybrids
displaying a mortal phenotype was only around 40%. This
is most likely explained by the relatively large fraction of the
transferred chromosomes that harbor deletions of the
candidate region (see below). However, it is also possible
that the effectiveness of the reintroduced chromosome may
be subject to clonal variation of the target cell population.
Chromosome 4 fragment analysis mapped the activity
crudely to a region bounded by the markers D4S2978–
D4S2975. Subsequent deletion analysis of immortal clones
resulting from the MMCT revealed a minimal 130-kb region
of loss of exogenous chromosome 4 alleles mapping to
between the markers BIR0110 and D4S1557, within the
D4S2978–D4S2975 interval. The region between D4S1570
and D4S2975 did show a significant level of loss at D4S406
and cannot, at this time, be excluded. However, we have
recently shown that a chromosomal fragment lacking the
region telomeric to BIR0101 can still induce mortality in
human squamous cell carcinoma cells [17]. Thus, we favor
the BIR0110–D4S1557 interval as the likely position of the
HeLa mortality gene also.
Mechanism of Action of the Mortality Gene
The HeLa cell line derives from a HPV18-positive cervical
adenocarcinoma. As a result of this, the viral oncoproteins
E6 and E7 disrupt, respectively, the p53 and pRB molecular
pathways and, as such, it is unlikely that the introduction of
chromosome 4 complements these defects in the control of
proliferative lifespan. It is also unlikely that cells with
compromised p53 and pRB can effect a genuine senescence
checkpoint; it seems probable therefore that chromosome 4
generates a phenotype more akin to crisis. It was recently
reported that the introduction of an exogenous copy of
chromosome 4 into HeLa cells resulted in the suppression of
the telomerase enzyme in a subset of hybrid clones and that
this correlated with the acquisition of a senescence- like
phenotype [3]. However, the average telomere restriction
fragment (TRF) length in a population of HeLa cells is 6.7 kb
[16,17]. This relatively long telomere length is inconsistent
with maximum number of divisions observed in the HeLa
clones displaying a phenotype following the introduction of
chromosome 4. Furthermore, a proportion of subclones of
HeLa cells has undetectable levels of telomerase activity [8 ];
therefore, it remains unclear whether the hybrid clones with
low telomerase activity result from this subpopulation of
cells. In a recent study, we have also shown that telomerase
activity is reduced in mortal clones of squamous cell
carcinoma cells harboring normal copies of chromosome 4
[17]. However, the phenotype is not reversed by ectopic
telomerase and is TRF length– independent [17]. This,
nonetheless, does not rule out the possibility that chromo-
some 4 acts to restrict the action of the telomerase enzyme
complex, or acts on the stability of the telomere structure
itself.
The Candidate Region may Contain a Tumor Suppressor In
Vivo
A number of tumor suppressor genes appear to have a
role in the control of human cancer immortality [24]. The
mortality gene at the locus, which we have identified, may be
a target for deletion in human cancer. Analysis of markers in
human tumors has detected loss of heterozygosity (LOH) at
loci that coincide with our candidate interval. Reports include
LOH in squamous cell carcinoma of the head and neck
[29,36,43], and also esophageal [20,32], cervical [18,25],
and hepatic carcinoma [10]. The candidate intervals iden-
tified for hepatocellular carcinoma [7] include an 18-Mb
interval centered on our locus. Moreover, this overlaps with a
hemizygous 8-cM germline deletion recently reported in a
case of hepatoblastoma [40]. The LOH studies are sup-
ported by comparative genomic hybridization investigations
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that detect a reduced dosage of 4q in breast [39], colon [2],
and prostate [42] carcinomas and a high incidence of loss
(86%) at 4q11-q23 in cases of small cell cancer of the lung
[29]. However, it should be stressed that there is no
evidence that any of the complementation group B lines,
including HeLa, shows monoallelic regions suggestive of
LOH. It is therefore possible that the chromosome 4 mortality
gene may be inactivated by mechanisms, such as biallelic
methylation in many cases, and the list of candidate tumor
suppressor genes that can be inactivated in this way is
expanding [4].
Further evidence to link our candidate region to tumor
development stems from a rare heritable skin disorder,
Huriez syndrome (MIM 181600), which can predispose to
squamous cell carcinoma of the skin and perhaps other
tissues. Linkage analysis and recombination events in
affected individuals have mapped this disorder to a 24-Mb
region [23], which spans our candidate interval. On a related
issue, a quantitative trait loci scan in individuals with
exceptional longevity found evidence for linkage to a region
on 4q [30]. This includes the region identified by our study
suggesting that the locus could also be associated with aging
in vivo.
Candidate Genes in the Region
No previously identified genes, spliced ESTs, or in silico
predicted genes are contained within, or overlap with the
BIR0110–D4S1557 candidate interval. The nearest gene
centromeric to this interval (90 kb from BIR0110) is ATOH1.
This encodes a basic helix– loop–helix domain-containing
molecule, which is the human homologue of the Drosophila
‘‘atonal’’ gene product [5]. It is proposed to play an im-
portant role in the development of the sensory epithelia of
the inner ear, but having a non-skin epithelial expression
pattern suggests that it is not a good candidate for the mor-
tality gene.
On the telomeric side, the ETL1 gene (also known as
SMARCAD1 [1 ] and KIAA1122 ) shows a relatively ubiq-
uitous expression and presents a more plausible candidate.
It is the human homologue of murine Etl1 [37] and may have
a role in ATP-driven chromatin remodeling through a SNF2-
related domain. The 50 end of the gene maps 160 kb distal to
D4S1557 and is only targeted by 23/30 of the deletions in the
most informative MMCT hybrid clones and by none of the
three small, discrete deletions (Figure 3B ).
To date, we have found no somatic mutations in ETL1 in
any cell lines, including HeLa and Northern blot analysis,
which showed that HeLa expressed equivalent levels of
ETL1 to normal keratinocytes (N. Barr, unpublished data).
This eliminates the possibility that a small reduction in the
dosage of the gene could contribute to the immortality of
HeLa cells.
A further candidate emerges from the sequence of a
single cDNA clone ( IMAGE 3935474), which maps onto
eight exons between 70 and 120 kb telomeric to D4S1557.
No open reading frame is evident within this expressed
sequence, although it has not been ruled out that more of this
gene remains to be identified. Preliminary experiments
suggest that this transcript is not expressed in primary
keratinocyte (epithelial ) cultures (data not shown), making it
an unlikely candidate.
Although it is possible that there may be a defect affecting
ETL1 protein expression that may have been undetected by
the methods we have used, it is more likely that another, as
yet unidentified, gene spanning the marker BIR0104 is
responsible for the mortality effect of chromosome 4. The
genome sequence for this region has now been completed
and presents an excellent resource to aid in the identification
of novel candidate genes in this interval.
In summary, the identification of the chromosome 4
mortality gene at the locus described here may well identify
additional pathways that must be disrupted in the immortal-
ization of human cancer cells and that may also contribute to
the aging of human cells in a more general way.
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